Phase I ABL001X2101: Novel BCR-ABL1 Inhibitor ABL001 Safe With Promising Activity in TKI-Resistant Chronic-Phase CML

Slideset - ABL001 showed early indications of clinical activity in chronic-phase CML patients both with and without TKI resistance mutations.
Source: Clinical Care Options Leukemia - Category: Hematology Source Type: research